Is VUG a Good ETF to Buy?
For the last few years, earnings growth from the tech…
Buy
62
SNY Quote, Financials, Valuation and Earnings
Last price:
$57.67
Seasonality move
:
5.11%
Day range:
$58.36 - $59.88
52-week range:
$45.22 - $60.12
Dividend yield:
6.7%
P/E ratio:
23.51x
P/S ratio:
3.06x
P/B ratio:
1.83x
Volume:
1.9M
Avg. volume:
2.6M
1-year change:
21.49%
Market cap:
$147.3B
Revenue:
$47.9B
EPS (TTM):
$2.50
Analysts' Opinion
-
Consensus RatingSanofi SA has received a consensus rating of Buy. The company's average rating is a Buy based on 5 Buy ratings, 2 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $63.58, Sanofi SA has an estimated upside of 8.25% from its current price of $58.74.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $62.00 representing -5.55% downside risk from its current price of $58.74.
Fair Value
-
According to the consensus of 7 analysts, Sanofi SA has 8.25% upside to fair value with a price target of $63.58 per share.
SNY vs. S&P 500
-
Over the past 5 trading days, Sanofi SA has overperformed the S&P 500 by 4.84% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Sanofi SA does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Sanofi SA has grown year-over-year revenues for 8 quarters straight. In the most recent quarter Sanofi SA reported revenues of $8.1B.
Earnings Growth
-
Sanofi SA has grown year-over-year earnings for 1 quarter straight. In the most recent quarter Sanofi SA reported earnings per share of $0.29.
Enterprise value:
156B
EV / Invested capital:
1.60x
Price / LTM sales:
3.06x
EV / EBIT:
19.74x
EV / Revenue:
3.25x
PEG ratio (5yr expected):
3.43x
EV / Free cash flow:
15.74x
Price / Operating cash flow:
14.21x
Enterprise value / EBITDA:
15.92x
Gross Profit (TTM):
$33.7B
Return On Assets:
4.36%
Net Income Margin (TTM):
12.61%
Return On Equity:
7.55%
Return On Invested Capital:
6.07%
Operating Margin:
11.28%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Income Statement | ||||||
| Revenue | $42.7B | $45.1B | $48B | $7.9B | $8.1B | |
| Gross Profit | $30.2B | $31.4B | $33.7B | $5.3B | $5.7B | |
| Operating Income | $11.5B | $9.9B | $10.3B | $793.7M | $917.8M | |
| EBITDA | $12.8B | $9.6B | $9.8B | -$739.8M | $600.1M | |
| Diluted EPS | $2.83 | $2.34 | $2.50 | -$0.24 | $0.29 | |
| Period Ending | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | -- | $34.7B | $36.6B | $33.9B | $44.3B | |
| Total Assets | -- | $136.1B | $135.9B | $139.8B | $138.2B | |
| Current Liabilities | -- | $24.1B | $25.7B | $26.8B | $30.3B | |
| Total Liabilities | -- | $58B | $55.3B | $57.6B | $57.2B | |
| Total Equity | -- | $78.2B | $80.6B | $82.2B | $81B | |
| Total Debt | -- | $23B | $20.4B | $18.1B | $16.6B | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-06-30 | 2023-06-30 | 2024-06-30 | 2023-06-30 | 2024-06-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -- | -- | -- | $3.9B | $1.5B | |
| Cash From Investing | -- | -- | -- | -$3.4B | -$3.7B | |
| Cash From Financing | -- | -- | -- | -$5.7B | $95.8M | |
| Free Cash Flow | $13.7B | $14B | $9.9B | $2.9B | -$498.5M | |
SNY
Sector
Market Cap
$147.3B
$36.4M
Price % of 52-Week High
97.71%
45.1%
Dividend Yield
6.7%
0%
Shareholder Yield
10.47%
-0.74%
1-Year Price Total Return
21.49%
-39.83%
Beta (5-Year)
0.586
0.773
Dividend yield:
6.7%
Annualized payout:
$2.04
Payout ratio:
83.62%
Growth streak:
1 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Buy
Level
$57.43
200-day SMA
Buy
Level
$51.99
Bollinger Bands (100)
Buy
Level
48.29 - 54.67
Chaikin Money Flow
Buy
Level
503.2M
20-day SMA
Buy
Level
$55.45
Relative Strength Index (RSI14)
Buy
Level
69.91
ADX Line
Buy
Level
47.44
Williams %R
Neutral
Level
-21.1051
50-day SMA
Buy
Level
$52.57
MACD (12, 26)
Buy
Level
1.75
25-day Aroon Oscillator
Buy
Level
84
On Balance Volume
Neutral
Level
87.7M
Financial Scores
--
Altman Z-Score
(Annual)
Level (--)
Buy
CA Score
(Annual)
Level (0.3195)
Buy
Beneish M-Score
(Annual)
Level (-2.7687)
Buy
Momentum Score
Level (6)
Buy
Ohlson Score
Level (-2.4271)
Buy
Piotroski F Score
(Annual)
Level (9)
Sell
Quality Ratio Score
Level (3)
Buy
Fundamental Score
Level (9)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, over-the-counter treatments and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 20% of total sales, but profits are shared with Regeneron. Just over 40% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Stock Forecast FAQ
In the current month, SNY has received 5 Buy ratings 2 Hold ratings, and 0 Sell ratings. The SNY average analyst price target in the past 3 months is $63.58.
-
Where Will Sanofi SA Stock Be In 1 Year?
According to analysts, the consensus estimate is that Sanofi SA share price will rise to $63.58 per share over the next 12 months.
-
What Do Analysts Say About Sanofi SA?
Analysts are divided on their view about Sanofi SA share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Sanofi SA is a Sell and believe this share price will drop from its current level to $62.00.
-
What Is Sanofi SA's Price Target?
The price target for Sanofi SA over the next 1-year time period is forecast to be $63.58 according to 7 Wall Street analysts, 5 of them rate the stock a Buy, 0 rate the stock a Sell, and 2 analysts rate the stock a Hold.
-
Is SNY A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Sanofi SA is a Buy. 5 of 7 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of SNY?
You can purchase shares of Sanofi SA via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Sanofi SA shares.
-
What Is The Sanofi SA Share Price Today?
Sanofi SA was last trading at $57.67 per share. This represents the most recent stock quote for Sanofi SA. Yesterday, Sanofi SA closed at $58.74 per share.
-
How To Buy Sanofi SA Stock Online?
In order to purchase Sanofi SA stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Does Intel Stock Have Room to Grow?
Intel Corporation (NASDAQ:INTC)’s recent innovations, Xeon 6 SoC and Xeon®…
Is Walmart the Largest Retailer in the World?
For many years, Walmart (NYSE:WMT) has been the world’s largest…
Stock Ideas
Sell
49
Is AAPL Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 36x
Sell
44
Is MSFT Stock a Buy?
Market Cap: $2.8T
P/E Ratio: 32x
Sell
45
Is NVDA Stock a Buy?
Market Cap: $2.7T
P/E Ratio: 37x
Alerts
Sell
50
GH alert for Mar 12
Guardant Health [GH] is up 1.1% over the past day.
Sell
44
TER alert for Mar 12
Teradyne [TER] is down 0.36% over the past day.
Buy
57
LMB alert for Mar 12
Limbach Holdings [LMB] is down 4.39% over the past day.
